Posted on

BETTER PLANT FDA-LISTED HAND SANITIZER GEL IS NOW AVAILABLE ON AMAZON.COM

Vancouver, B.C. – November 3, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its Urban Juve Hand Sanitizer Gel, which was recently listed by the FDA, is now live and available for purchase on Amazon.com.

The Hand Sanitizer Gel is also available for sale on UrbanJuve.com, Amazon.ca, and select retail partners such as Pharmasave, Vitasave, and YesWellness in Canada.

“We have had a lot of interest in this product since its launch earlier this year; hand sanitizer is an extremely important tool in the fight against the COVID-19 pandemic, as well as the seasonal cold and flu. Consumers are also realizing how important a product with natural and high-quality ingredients is to use long-term to not only disinfect their hands, but to protect and nourish them as well,” says Gabe Villablanca, Better Plant’s Director of eCommerce. “So far, early feedback on the product has been overwhelmingly positive.”

The Hand Sanitizer Gel will be sold in packs of three for USD $21.99. The product page can be accessed here. The hand sanitizer gel contains 65% ethyl alcohol as well as aloe vera and eucalyptus oil, which can help to combat skin dryness: a common side effect of many hand sanitizers. It also contains tea tree oil and cedarwood essential oils which give it increased antimicrobial activity as well as a fresh outdoorsy scent that has garnered positive feedback from consumers and retailers alike.

The hand sanitizer gel is listed with the FDA (NDC 75385-0010-1) and has received Natural Health Product Number 80098154 from Health Canada. Urban Juve’s Ultra Hydrating Hand Sanitizer Spray received Health Canada approval on March 27, 2020.

Sales of hand sanitizer are expected to reach US $11 billion in 2020, a 600% increase over 2019. The hand sanitizer market is expected to grow at a CAGR of over 17% between 2019 and 2025 according to a report from Aritzon.

According to a report by Statista.com, as of December 2019, there were an estimated 112 million U.S. Amazon Prime subscribers, up from 95 million in June 2018. On average, Amazon Prime members spent 1,400 U.S. dollars on the e-retail platform per year.

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby, and home under the brands JUSU, Urban Juve and Wright & Well. Its majority owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@betterplantsciences.com 

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved, or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT AFFILIATE NEONMIND CLOSES OVERSUBSCRIBED INITIAL PUBLIC OFFERING AND EXERCISE IN FULL OF THE AGENT’S OVER-ALLOTMENT OPTION

Vancouver, B.C. –  December 31, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) is pleased to announce that its partially owned subsidiary NeonMind Biosciences Inc. (“NeonMind”) has successfully completed the maximum offering for its initial public offering (the “IPO”) of 46,000,000 units of NeonMind (the “Units”) at a price to the public of $0.10 per Unit, including 6,000,000 in additional Units pursuant to the exercise in full of the over-allotment option. The gross proceeds from the IPO, before deducting agent fees and estimated offering expenses, were $4.6 million.  NeonMind’s common shares were listed on the Canadian Securities Exchange (the “Exchange”) on December 29, 2020 and were immediately halted pending the closing of the IPO.  Trading of NeonMind’s common shares on the Exchange will resume at market open on Monday, January 4, 2021 under the ticker symbol “NEON”.

Each Unit consists of one common share of NeonMind and one share purchase warrant to purchase one additional common share of NeonMind at a price of $0.20 per share until December 30, 2021.

Pursuant to an agency agreement dated December 8, 2020, Mackie Research Capital Corporation (the “Agent“) acted as agent for NeonMind in connection with the IPO.  NeonMind paid the Agent and members of its selling group a cash commission equal to 10% of the gross proceeds of the IPO and granted the Agent and members of its selling group non-transferable warrants to purchase up to an aggregate of 4,600,000 units in NeonMind for $0.10 per unit until December 30, 2022, with each unit consisting of one common share of NeonMind and one share purchase warrant to purchase one additional NeonMind common share at a price of $0.20 per share until December 30, 2022. NeonMind also paid the Agent a corporate finance fee of $45,000 plus GST, and reimbursed the Agent for its legal fees and reasonable expenses.

NeonMind expects to use the proceeds from the IPO to complete its preclinical trial using psilocybin and complete protocols for its planned phase 2 human clinical trial, as well as to market its recently launched line of medicinal mushroom coffees.

After completion of the IPO, NeonMind now has 112,430,500 common shares issued and outstanding on a non-diluted basis, of which 51,713,500 common shares will be subject to escrow.

Better Plant currently owns 33,313,500 NeonMind Shares out of 112,430,500 NeonMind common shares currently issued and outstanding.  Better Plant also owns 55,000,0000 warrants to purchase NeonMind common shares at $0.20 per share until May 6, 2022. The NeonMind shares and warrants owned by Better Plant are subject to an escrow agreement whereby the securities will be released in tranches over a 35 month period, beginning 30 days after December 29, 2020. Currently, Better Plant owns approximately  29.6%  of the outstanding and issued NeonMind common shares on a non-diluted basis.

The listing of NeonMind on the Exchange will not affect the listing of Better Plant and Better Plant’s common stock will continue to trade on the Exchange under the ticker symbol “PLNT”, and continue to trade on the OTCQB under the ticker symbol “VEGGF”.

 

About NeonMind Biosciences Inc.

NeonMind is developing and commercializing products that contain legal medicinal mushrooms and products that may contain psychedelic compounds. Its first proposed drug candidate involves the administration of psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and related illnesses for which NeonMind has started a preclinical trial at the University of British Columbia.  NeonMind has filed 5 US provisional patent applications claiming methods of aiding in weight loss, treating compulsive eating disorder, treating obesity or a complication of obesity,  and/or altering the diet of an individual by administering psilocybin and/or other psychedelic  compounds or their analogs or by administering psilocybin or its analog in conjunction with therapy or other treatments. NeonMind is also pursuing commercialization of its catalogue of  proprietary medicinal mushroom product formulas. It recently launched a collection of 4 mushroom infused coffees under the NeonmindTM brand which are infused with medicinal mushrooms: Lion’s Mane, Turkey Tail, Reishi and Cordyceps.

 

About Better Plant Sciences Inc.

Better Plant offers plant-based products for optimum health and wellness. It is a vertically integrated company with a team whose complementary experience enables acquisition, development, manufacturing, and direct-to-consumer distribution of its products. Its all-natural products vary in use from pain treatment to disease prevention to skin care, all without chemicals or harmful ingredients. It has an extensive catalogue of over 400 proprietary product formulas. Better Plant currently has over 70 plant-based products for sale through eCommerce and/or in retail stores under the brands Jusu, Urban Juve, and Wright & Well. Better Plant also owns approximately 29.6% of NeonMind.

For more information about Better Plant, visit betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Director of Investor Relations

invest@betterplantsciences.com

1-833-515-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or NeonMind and Better Plant’s  future performance. The use of any of the words “could”, “expect”, “believe”, “will”, “projected”,”estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on Better Plant management’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, NeonMind’s stated use of proceeds and its expectation as to the resumption of trading of its common shares on the Exchange constitute forward-looking information. Actual results and developments may differ materially from those contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-looking information. The statements made in this press release are made as of the date hereof. NeonMind disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as may be expressly required by applicable securities laws.

Posted on

BETTER PLANT RECEIVES HEALTH CANADA APPROVAL FOR PLANT-BASED ANTISEPTIC SKIN OINTMENT

Vancouver, B.C. – October 29, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) announces that it has received a Natural Health Product (“NHP”) number (#80105697) from Health Canada for its plant-based, antimicrobial, antiseptic skin ointment. This product was developed after promising results from the Company’s research of certain plant-based compounds for antimicrobial activity against pathogens for potential antiviral treatments. This will be Better Plants fourth Health Canada approval in 2020.

 

“This antiseptic skin repair and healing ointment formula was developed over ten months and is based on the ancient principles of Ayurveda. It uses plants containing natural compounds that work powerfully to fight bacteria and viruses and contains powerful plant oils with antibacterial and antifungal compounds,” says Penny White, CEO of Better Plant. “It is ideal for minor skin wounds, sores, and bruises.”

 

All NHPs sold in Canada require premarket approval. The health claim that was approved for Urban Juve’s infectious disease fighting ointment is: “Traditionally used in Herbal Medicine as an antiseptic and/or antimicrobial to help treat minor wounds and sores.” Better Plant’s skin healing ointment uses polyherbal combinations to achieve an effective therapeutic effect. Key ingredients include thyme, copaiba, and clove essential oil, which all have wound healing properties. “Polyherbal formulations use a group of plants, combined precisely based on the principles of Ayurveda,” says Bhavna Solecki, Director of Research and Product Development for Better Plant.

 

According to a 2018 Market Study Report, the global wound care biologics market is expected to reach USD $2.9 billion by 2025. The global market is segmented on the basis of product, wound type, end user, and region. By product, the market segmented into biological skin substitutes and topical agents. The biological skin substitutes segment is estimated to account for the largest share of the market in 2018.

 

“Traditional medicine and healers have long used plants to prevent or cure infectious disease,” says Bhavna Solecki, Director of Research and Product Development for Better Plant. “The active compounds available in plants have high therapeutic value. Western medicine has begun duplicating ancient medicine with success, and microbiologists, botanists and natural product chemists are becoming more involved in researching plant phytochemicals for treatment of infectious disease.”

 

Better Plant also welcomes Joelle Fiorito who has been appointed as Director of Operations. Joelle has overseen operations for Jusu since the brand was created in 2014. Joelle will take on some of the duties of Tamara Melk, who is now leaving Better Plant as  Chief Operating Officer.

 

About Better Plant Sciences Inc.

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant-based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its 51% majority owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

T1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

NEONMIND MANUFACTURES 4 SUPERFOOD MUSHROOM COFFEES

Vancouver, B.C. – October 27, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”)  is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed an initial production run of all four of its Ayurvedic, functional mushroom coffees.

 

“With this production run successfully completed, we are now prepared to begin consumer testing. We are also lining up distribution and are preparing to begin tests for digital  marketing for the website prior to its launch,” said Penny White, CEO of Better Plant. “We are excited to be able to fulfill the growing consumer appetite for functional food products that promote good health.”

 

Functional foods are food that are demonstrated to have physiological benefits and/or reduce the risk of chronic disease beyond just providing nutrition alone.

 

This production run includes four unique SKUs, which are all infused with Ayurveda botanicals:

 

Two instant superfood mushroom coffee blends for on-the go:

 

  • Rest Blend: Contains Lion’s Mane, Reishi, Ashwagandha and Turmeric
  • Energize Blend: Contains Turkey Tail, Cordyceps, Holy Basil and Moringa

 

Two traditional roasted superfood mushroom coffee blends:

 

  • Focus Blend (Dark Roast): Contains Lion’s Mane, Reishi, Gotu Kola, Brahmi
  • Protect Blend (Medium Roast): Turkey Tail, Cordyceps, Moringa and Amla

 

“When selecting partners such as a co-packer for functional food production, it is crucial to find alignment on safety, nutrition, quality and values,” said Bhavna Solecki, Director of Research and Product Development for Better Plant. “Production facilities should have suitable techniques, methods, and tools, to keep and enrich the nutritive values and bioactivity of the products, as well as  be able to propose future directions for food analytical methodologies to refine the process of sorting, grinding, conveying, processing and packaging systems. They must also be able to provide nutritional facts and quality of food and contents of nutrients and bio active components using third party analysis”

 

Each batch also goes through third party microbial testing with a certificate of analysis issued by the facility to enhance the homogeneity and stability of the final product for storage and shelf life.

 

Grand View Research reported in 2019 that the functional foods market is expected to reach USD $275.77 billion by 2025.

 

About NeonMind Biosciences Inc. 

 

NeonMind is engaged in research and development of products that use medicinal and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and plans to soon begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 50% of the issued and outstanding stock of NeonMind.

 

About Better Plant Sciences Inc.


Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its 50% majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT RECEIVES HEALTH CANADA APPROVAL FOR PLANT-BASED PAIN BALM

Vancouver, B.C. – October 22, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) announces that its subsidiary Urban Juve Provisions Inc., has received a Natural Health Product (“NHP”) number from Health Canada for its proprietary plant-based pain balm. Health Canada’s Natural and Non-Prescription Health Products Directorate has concluded that Urban Juve’s application is in compliance pursuant to section 7 of the Natural Health Products Regulations and issued NHP number 80105503.

“We are thrilled that our unique pain relief formula based on Ayurvedic principles is now approved by Health Canada,” says Penny White, CEO of Better Plant. “This allows us to sell and distribute the product ourselves with the potential to white label the product with other strategic partners and brands.”

All-natural health products sold in Canada require premarket approval. The health claim that was approved for Urban Juve’s pain balm efficacy is: “temporarily relieves back aches and pains of muscles and joints associated with one or more of the following: simple backache, lumbago, strains and sprains (involving muscles, tendons, and/or ligaments), and arthritis.”

“One has to think one step ahead to anticipate the challenges for regulatory approvals of NHP products,” says Bhavna Solecki Director of Product Research for Better Plant. “We have been successful obtaining multiple NHP approvals, which we are very proud of, considering the required health claim substantiation, theoretical product review, scientific literature review and product classification.”

Better Plant’s pain balm uses a synergetic and proprietary blend of plant-based ingredients. Menthol crystals act as an anti-irritant and provide a heating/cooling effect by sending a signal to the brain which interprets the feeling as cold, relieving the uncomfortable heat of inflammation.

Some studies estimate that up to 40% of the population suffers from chronic pain. Arthritis is the most prevalent health condition in Canada, and its most common form is osteoarthritis which is a leading cause of disability worldwide. Other common causes of chronic pain include gout, rheumatoid arthritis, fibromyalgia, lupus and carpal tunnel syndrome which is increasingly affecting youth, from excessive typing and texting.

According to a report by BCC Research, the global market for pain management will grow from nearly USD$36.1 billion in 2017 to USD$52.0 billion by 2022, with a compound annual growth rate (CAGR) of 7.6% for the period of 2017-2022.

 

About Better Plant Sciences Inc.

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant-based products for body, baby, and home under the brands JUSU, Urban Juve and Wright & Well. Its 51% majority owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political, and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better Plant cautions readers not to place undue reliance on forward-looking statements provided by Better Plant, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

NEONMIND SUPERFOOD MUSHROOM COFFEE UPDATE

Vancouver, B.C. – October 20, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”)  is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has completed production of two out of four of its superfood mushroom coffee blends. The first NeonMind Superfood instant coffees will be ready to ship to their warehouse in early November. The initial two formulas are an Ayurveda-inspired blend of reishi, lions mane, ashwagandha and turmeric with premium instant coffee. The functional mushrooms are antioxidant and nutrient-rich, with adaptogenic, immune-boosting properties. The Company plans to launch its eCommerce website in November and will rely heavily on influencer marketing to educate a broader consumer base on the taste and health benefits of mushroom coffees.

 

“Functional mushrooms are increasing in popularity for their ability to increase mental clarity, as well as for their range of health benefits, including immune support and energy-boosting qualities,” said Penny White, CEO of Better Plant Sciences. “We have formulated our coffees to be both healthy and delicious, and our instant blend is convenient, easy, and perfect for those on the go or those who are only looking to enjoy one cup at a time.”

 

Having just completed manufacturing of the two instant coffee blends, they will now undergo third-party testing as required by Health Canada regulations, and are expected to be ready to ship to our warehouse in early November. They will then begin manufacturing two brewed coffee formulations, with production to be followed by the same required third-party testing. The brewed coffees are expected to be ready to ship to our warehouse in mid-November. All four products have been registered with Vancouver Coastal Health. The Company’s plan is to commercially launch the mushroom coffees via a new eCommerce website in late November 2020.

 

The global functional mushroom market is expected to reach USD$78.7 billion by 2025, from USD$38.1 billion in 2017 growing at a CAGR of 9.5% during the forecast period of 2018 to 2025, according to Data Bridge Market Research.

 

About NeonMind Biosciences Inc. 

NeonMind is engaged in research and development of products that use functional and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 69% of the issued and outstanding stock of NeonMind.

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT COMPLETES ACQUISITION OF JUSU

Vancouver, B.C. – October 14, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce the completion of its acquisition of Jusu, a Canadian health, wellness and lifestyle brand that focuses on premium plant-based products. The acquisition consisted of the purchase of  assets of Jusu Bars Inc., Jusu Body Inc. and Jusu CBD Inc. in an all stock deal for $2,225,000. Better Plant now carries on these businesses through its wholly owned subsidiary Jusu Wellness Inc.  These assets are in addition to the Better Plant owned wellness brands Urban Juve, Wright & Well and NeonMind. The combined business of Better Plant now has over 400 product formulas in its catalogue and over 150 different products currently for sale under various brands.

“Jusu is an excellent addition to the Better Plant portfolio. We are focused on bringing the most innovative and premium plant-based products to market to help our customers optimize their health, and well-being,” said Penny White, CEO of Better Plant. “Our plan is to grow the Jusu business, which is currently generating revenues of approximately $60,000 per month, by optimizing sales through eCommerce channels, strengthening the brand and product offering, as well as expanding through a franchise model.”

The purchased assets include all inventory, packaging, raw ingredients, and intellectual property related to JUSU’s 300 plant-based products for the home, body and baby, as well as the eCommerce sites that sell Jusu products, customer lists, certain juice bar equipment, and all tangible assets relating to the Jusu Bar retail location in Cadboro Bay, Victoria.

The agreed purchase price for the acquisition was 22,000,000 units of Better Plant at a deemed price of $0.10 per unit (after payment of $25,000 for inventory on September 1, 2020), with each unit consisting of one common share and one warrant to purchase a common share at $0.11 per share for two years. Of those units, 19,000,000 units were issued at closing on October 9, 2020.  3,000,000 units were held back as security to ensure that Jusu Body Inc. and Jusu Bars Inc. are discharged from certain general security registrations. The unit shares are subject to a stock restriction agreement restricting sale of the units for four months after the date of issuance, and after that no more than 30,000 shares per day. Better Plant agreed to pay a bonus of 2.5 million units upon reaching $5 million in Jusu product sales within 3 years.

Pursuant to the acquisition, Better Plant will book revenues from all Jusu sales beginning October 9, 2020.  The Jusu plant-based product sales for home, body and baby have historically been approximately $40,000 per month, with a gross profit margin of approximately 60%, not including marketing or overhead.  Direct to consumer juice sales have only recently launched and  have had a profit margin of approximately 65%, although this is expected to decrease to 30% due to disruption in supply.  Jusu Bars Inc. shall continue to operate the juice business for a period of 120 days for a fee of 5% of such revenues payable to Better Plant as an operator fee.  Jusu Bars shall pay for operating expenses and bill them back to Better Plant on a monthly basis, but operating expenses and operator fees in aggregate may not exceed the net revenues each month.  Better Plant did not assume any of the liabilities of Jusu outstanding at closing.

In connection with the acquisition, Bruce Mullen, the founder of Jusu, has joined the board of directors of Better Plant.  Since 2014 Bruce Mullen has been active as the largest shareholder and the director and chief executive officer of the Jusu companies.  Penny White has resigned as director of Better Plant but she continues as CEO & President of Better Plant and its subsidiary companies, including Jusu Wellness.

Prophecy Market Insights reported that the global vegan beauty products market is estimated to reach USD$25.3 billion by 2029 with a CAGR of 5.9% between 2019 and 2029. Meticulous Research reported that the plant-based food market is expected to grow at a CAGR of 11.9% from 2020 to 2027 to reach USD$74.2 billion by 2027.

All references to currency in this press release are in Canadian dollars unless otherwise noted.

 

About Jusu Wellness Inc.

Jusu Wellness Inc. is a wholly owned subsidiary of Better Plant and it owns and operates Jusu,  a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant based products. Jusu is committed to making pure, organic, plant-based products for consumption, body and personal care. This includes one JUSU Bar location and brick-and-mortar juice bar franchise opportunities as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, aromatherapy and home cleaning lines. Jusu is fully dedicated to offering consumers healthier alternatives to currently available chemical-based skin care, edible, and beverage products.

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It owns over 400 proprietary product formulas.  It operates websites and sells through eCommerce, Amazon and through a retail store network over 150 plant based products for body, baby and home under the brands JUSU, Urban Juve and Wright & Well. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for Health Canada approval to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of COVID-19, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

NEONMIND SIGNS PSILOCYBIN SUPPLY AGREEMENT FOR CLINICAL TRIALS

Vancouver, B.C. – September 29, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that its majority owned subsidiary NeonMind Biosciences (“NeonMind”) has entered into a definitive agreement with Psygen Labs Inc. (“Psygen”) for the supply of psilocybin for NeonMind’s planned  preclinical, and clinical trials  to study the use of a drug product including Psilocybin for the treatment of food cravings and anxiety. The agreement was signed on September 28th, 2020.

Psygen is currently acting as broker between NeonMind and a licensed dealer of restricted drugs (the “Licensed Dealer“). The Licensed Dealer holds a dealer’s licence issued under Part J of the Food and Drug Regulations (a “Dealer’s Licence“). The Supply Agreement provides that Psygen will supply the psilocybin directly once Psygen holds a Dealer’s License. Psygen currently has a pending application for a Dealer’s License.

“Psilocybin is known to activate serotonin receptors,” says Dr. William Panenka, lead scientific advisor to NeonMind. “As a neurotransmitter, serotonin helps to relay messages from one area of the brain to another. Serotonin is responsible for some of the drivers which govern eating. We are very interested in furthering studies to test various dosing regimens for NeonMind to see the effects that psilocybin may have on the serotonin receptors that regulate food cravings.”

“Psygen’s mission is to fill a supply gap for restricted drug substances and restricted drug products for use in clinical trials and in pre-clinical research,” says Danny Motyka, CEO of Psygen Labs Inc. “We have brokered supply of various restricted drugs for pre-clinical studies and clinical trials through our relationship with a Licensed Dealer. Psygen is currently building out a commercial manufacturing facility designed for high-volume output of psychedelic drug substances and drug products, filling a niche in the evolving psychedelic medicine ecosystem. Today these psychedelic drug substances are classified as restricted drugs, meaning no recognized medical use in Canada, and we are playing our part in moving those substances to the controlled drugs schedule of the Food and Drug Regulations or otherwise providing compliant access to psilocybin and other psychedelics.”

In December 2019, NeonMind filed a U.S. provisional patent application in the United States for the invention relating to therapeutic administration of psilocybin to provide weight loss benefits and potential treatment or regulation of diabetes, and regulation of blood glucose, and to reduce susceptibility to cardiovascular disease, high blood pressure, diabetes mellitus, hypertension, multiple sclerosis, erectile dysfunction, urinary incontinence, chronic renal failure, sleep apnea, asthma, and certain forms of cancer.

In May 2020, NeonMind completed the design of a preclinical trial to confirm that psilocybin is an effective treatment for weight loss and food cravings (the “Trial“). In July 2020, the scientific investigator chosen to lead NeonMind’s preclinical trial submitted a Section 56 Exemption application to Health Canada for the use of psilocybin in the Trial. An exemption must be granted and a final agreement entered into with the laboratory before the Trial can begin.

According to the World Health Organization, in 2016, more than 1.9 billion adults or 39% of adults, 18 years and older, were overweight. Grandview Research projects that the global weight management market is expected to grow at a compound annual growth rate of 8.3% from 2019 to 2025 to reach USD $442.3 billion by 2025.

 

About Psygen Labs Inc.

Psygen is a privately held company based in Calgary, Alberta. Psygen specializes in synthetic manufacture of psychedelic drug substances and drug products. Psygen provides non-exclusive access to GMP compliant psychedelic drug substances and drug products for clinical trials, therapeutic applications and pre-clinical studies. Psygen has entered into a number of definitive agreements for ongoing supply of drug substances and is positioned to be a lead supplier in the emerging commercial market for psychedelic drug substances and drug products. Psygen has sponsored a Licensed Dealer who holds a license for the manufacture, sale, import, export, and analysis of LSD, psilocybin, MDMA, DMT, 2C-B, and mescaline. Chemists working with Psygen currently operate from a manufacturing laboratory at the University of Alberta. Psygen has applied to Health Canada for a Dealer’s License that will allow Psygen to manufacture, possess, sell, import, export, research, develop, and analyze psychedelic drug substances and drug products. Psygen is currently building out a 6,000 square foot lab capable of large-scale synthesis, formulation and distribution of the above and additional psychedelics to a GMP standard. Psygen intends to be the leader in psychedelic medicine supply chain solutions and is committed to supporting the renaissance in use of psychedelics for research and clinical treatment of a wide variety of mental health issues.

 

About NeonMind Biosciences Inc.

NeonMind is engaged in research and development of products that use functional and psychedelic mushrooms to optimize human health and performance. The company is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents. NeonMind owns 18% of Translational Life Sciences Inc. Better Plant Sciences owns approximately 69% of the issued and outstanding stock of NeonMind.

 

About Better Plant Sciences Inc.

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing functional mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen. Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets. Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT ANNOUNCES JUSU JUICES NOW AVAILABLE FOR HOME DELIVERY IN VICTORIA

Vancouver, B.C. – September 22, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that JUSU Bar juices are now available for online order in Victoria through www.jusubaryyj.com for home delivery.

JUSU Bar currently has one retail juice bar location open in Victoria, British Columbia, and is now delivering cold-pressed JUSU juices directly to customers through its eCommerce store. Better Plant plans to continue expansion of the juice delivery program across Canada and the U.S. over the next year.

“JUSU was launched in Victoria, with this store, in November of 2014, and since then, the company has grown a loyal local community while expanding the brand beyond British Columbia,” said Penny White, CEO of Better Plant Sciences. “Today’s busy lifestyles mean that people are eating fewer fruits and vegetables, so juicing has become an easy way to increase nutritional uptake, boost the immune system, improve digestion, clear up skin issues and  encourage better eating habits. Our gut is the foundation of our health.”

JUSU juices are available for purchase in brick-and-mortar locations including JUSU Bar at Cadboro Bay, Whole Foods, Red Barn Markets, Root Cellar and Lifestyles Markets. In both Calgary and Victoria, JUSU juices can be ordered online for home delivery.

“Organic cold-pressed juice is the perfect fuel to help everyone look after their immune systems, and it has never been more important to do so,” said JUSU Founder, Bruce Mullen. “We have no-contact delivery and pickup available to keep our customers safe.”

The following six cold-pressed JUSU juices are available as singles or as part of 1, 3 and 5-day cleanses:

  • Green Machine
  • Hawkeye
  • Emerald City
  • Blue Lagoon
  • Dirty Lemonade
  • Classic

A report by Technavio projected that the global cold-pressed juice market is poised to grow by USD $275.5 million during 2019-2023, progressing at a CAGR of almost 8% during the forecast period.

On August 19, 2020, Better Plant announced that it had entered into an agreement to acquire JUSU branded plant-based assets from JUSU Bar Inc., JUSU Life Inc. and JUSU Cbd Inc. The acquisition is expected to close within the next 30 days.

 

About JUSU

JUSU is a full spectrum wellness brand with a mission to enlighten consumers to the protective and effective properties of plant based products. Its group of companies is committed to making pure, organic, plant-based products for consumption, body and personal care. This includes one JUSU Bar location and brick-and-mortar juice bar franchise opportunities as well as an extensive direct-to-consumer product offering including cold-pressed juices, skin care and body products, aromatherapy and home cleaning lines. JUSU is fully dedicated to offering consumers healthier alternatives to currently available chemical-based skin care, edible, and beverage products. All JUSU Group companies provide customers only the highest-quality all-natural products made from 100% natural, non-GMO ingredients and operate under the moto: Great products for great people.

 

About Better Plant Sciences Inc.

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has 14 patent applications to protect its Intellectual Property, and over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Kevan Matheson, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

Posted on

BETTER PLANT ANNOUNCES WRIGHT & WELL PACKAGING ACCLAIMED BY LEADING DESIGN PUBLICATIONS

Vancouver, B.C. – September 17, 2020: Better Plant Sciences Inc. (CSE: PLNT) (OTCQB: VEGGF) (FSE: YG3) (“Better Plant”) or (the “Company”) is pleased to announce that subsidiary Wright & Well, which creates high-end THC and CBD infused topicals and tinctures, has been recognized by two leading publications for it’s packaging design.

Packaging of the World and The World of Brand Design Society have featured Wright & Well’s packaging online. Packaging of the World is one of the most prominent package design websites showcasing the most interesting and creative work worldwide. The World Brand Design Society is the home of consumer and corporate brand design.

“When we were designing the Wright & Well packaging, we wanted to convey quality, elegance and wellness, while making the unboxing experience unique and memorable,” said Perry Chua, Creative Director for Better Plant Sciences. “It is an honour to be recognized by these publications in the packaging design industry.”

Wright & Well consists of an Ayurveda-inspired collection of THC- and CBD-infused products. Using high quality Cannabis Sativa (Hemp) Root Oil, crafted through an exclusive proprietary extraction process, Wright & Well’s first five products include 2 CBD tinctures regular and extra strength, an analgesic topical gel, pain balm and massage oil. The products are currently sold in Oregon through licensed distributor Nova Paths.

 

About Better Plant Sciences Inc. 

Better Plant develops and acquires intellectual property and other assets related to plant-based products and therapeutics. Through its integrated business model, Better Plant develops, manufactures, markets, sells and distributes plant-based products. It has over 200 proprietary wellness formulas at various stages of commercialization, including over 20 proprietary products that are now for sale via eCommerce or brick-and-mortar retail stores. It operates websites and oversees eCommerce and Amazon sales for over 200 JUSU plant based products for body, baby and home and has announced it will acquire all JUSU Bar Inc. assets. Its majority-owned subsidiary NeonMind Biosciences Inc. is launching a line of coffees infused with health optimizing medicinal mushrooms including reishi, cordyceps, lion’s mane and turkey tail mushrooms. NeonMind is also engaged in research into developing a psilocybin (psychedelic mushroom) based product for weight loss and has applied for a Section 56 Exemption to begin preclinical trials to study its pending psychedelic medicine patents.

For more information about Better Plant, visit www.betterplantsciences.com or follow @betterplantsciences on Instagram.

 

Investor Relations Contact:

Penny White, President & CEO

Ali Dumanski, Investor Relations

invest@betterplantsciences.com

1-833-514-2677

The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.

 

Cautionary Statement Regarding Forward-Looking Statements

This press release includes forward-looking information and statements (collectively, “forward looking statements”) under applicable Canadian securities legislation.  Forward-looking statements are necessarily based upon a number of estimates, forecasts, beliefs and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause actual results and future events to differ materially from those expressed or implied by such forward-looking statements.  Such risks, uncertainties and factors include, but are not limited to: risks related to the development, testing, licensing, brand development, availability of packaging, intellectual property protection, reduced global commerce and reduced access to raw materials and other supplies due to the spread of the Coronavirus, the potential for not acquiring any rights as a result of the patent  application and any products making use of the intellectual property may be ineffective or the company may be unsuccessful in commercializing them; and other approvals will be required before commercial exploitation of the intellectual property can happen.  Demand for the company’s products, general business, economic, competitive, political and social uncertainties, delay or failure to receive board or regulatory approvals where applicable, and the state of the capital markets.  Better cautions readers not to place undue reliance on forward-looking statements provided by Better, as such forward-looking statements are not a guarantee of future results or performance and actual results may differ materially. The forward-looking statements contained in this press release are made as of the date of this press release, and Better expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.